Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation - PubMed

Affiliations

• PMID: 20097881
• DOI: 10.1182/blood-2009-11-253070

Free article

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation

Wen-Chien Chou et al. Blood. 2010.

Free article

Abstract

Mutations of nicotinamide adenine dinucleotide phosphate-dependent isocitrate dehydrogenase gene (IDH1) have been identified in patients with gliomas. Recent genome-wide screening also revealed IDH1 mutation as a recurrent event in acute myeloid leukemia (AML), but its clinical implications in AML are largely unknown. We analyzed 493 adult Chinese AML patients in Taiwan and found 27 patients (5.5%) harboring this mutation. IDH1 mutation was strongly associated with normal karyotype (8.4%, P = .002), isolated monosomy 8 (P = .043), NPM1 mutation (P < .001), and French-American-British M1 subtype (P < .001), but inversely associated with French-American-British M4 subtype (P = .030) and expression of HLA-DR, CD13, and CD14 (P = .002, .003, and .038, respectively). There was no impact of this mutation on patient survival. Sequential analysis of IDH1 mutation was performed in 130 patients during follow-ups. None of the 112 patients without IDH1 mutation at diagnosis acquired this mutation at relapse. In all 18 IDH1-mutated patients studied, the mutation disappeared in complete remission; the same mutation reappeared in all 11 samples obtained at relapse. We conclude that IDH1 is associated with distinct clinical and biologic characteristics and seems to be very stable during disease evolution.

Comment in

• A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.

  Chou WC, Huang YN, Huang CF, Tseng MH, Tien HF. Chou WC, et al. Blood. 2010 Jul 22;116(3):495-6. doi: 10.1182/blood-2010-04-280636. Blood. 2010. PMID: 20651083 No abstract available.

Similar articles

• [IDH1 Gene Mutation and Its Clinical Significance in patients with Acute Myeloid Leukemia].

  Wei JF, Qiu HY, Chen GH, Wang Y, Chen Z, Liu HJ, Mao JP, Jia T, Xue LG, Cai ZM, Zhu YX, Zhao LD. Wei JF, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1252-7. doi: 10.7534/j.issn.1009-2137.2015.05.006. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015. PMID: 26524018 Chinese.

• Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.

  Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Ok CY, et al. Haematologica. 2019 Feb;104(2):305-311. doi: 10.3324/haematol.2018.191148. Epub 2018 Aug 31. Haematologica. 2019. PMID: 30171025 Free PMC article.

• [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].

  Wei H, Zhang YQ, Lin D, Wang Y, Zhou CL, Liu BC, Li W, Rao Q, Wang M, Mi YC, Wang JX. Wei H, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):11-5. doi: 10.7534/j.issn.1009-2137.2014.01.003. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014. PMID: 24598642 Chinese.

• IDH mutations in glioma and acute myeloid leukemia.

  Dang L, Jin S, Su SM. Dang L, et al. Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Trends Mol Med. 2010. PMID: 20692206 Review.

• Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.

  Akiyama M, Yamaoka M, Mikami-Terao Y, Ohyama W, Yokoi K, Arakawa Y, Takita J, Suzuki H, Yamada H. Akiyama M, et al. Int J Hematol. 2015 Dec;102(6):723-8. doi: 10.1007/s12185-015-1892-z. Epub 2015 Oct 27. Int J Hematol. 2015. PMID: 26508204 Review.

Cited by

• Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.

  Song MK, Park BB, Uhm JE. Song MK, et al. Int J Mol Sci. 2021 May 28;22(11):5789. doi: 10.3390/ijms22115789. Int J Mol Sci. 2021. PMID: 34071627 Free PMC article. Review.

• Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.

  Liu X, Gong Y. Liu X, et al. Biomark Res. 2019 Oct 22;7:22. doi: 10.1186/s40364-019-0173-z. eCollection 2019. Biomark Res. 2019. PMID: 31660152 Free PMC article. Review.

• Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.

  Chan SM, Majeti R. Chan SM, et al. Int J Hematol. 2013 Dec;98(6):648-57. doi: 10.1007/s12185-013-1407-8. Epub 2013 Aug 15. Int J Hematol. 2013. PMID: 23949914 Free PMC article. Review.

• Potato glycoside alkaloids exhibit antifungal activity by regulating the tricarboxylic acid cycle pathway of Fusarium solani.

  Zhang C, Chen W, Wang B, Wang Y, Li N, Li R, Yan Y, Sun Y, He J. Zhang C, et al. Front Microbiol. 2024 Apr 15;15:1390269. doi: 10.3389/fmicb.2024.1390269. eCollection 2024. Front Microbiol. 2024. PMID: 38686115 Free PMC article.

• The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis.

  Yonal-Hindilerden I, Daglar-Aday A, Hindilerden F, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS, Sargin D. Yonal-Hindilerden I, et al. J Clin Med Res. 2016 Jan;8(1):29-39. doi: 10.14740/jocmr2405w. Epub 2015 Dec 3. J Clin Med Res. 2016. PMID: 26668680 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal